Outcomes of second-targeted therapy for mRCC: A retrospective chart review of community practices in the United States.
Eric Jonasch
Consultant or Advisory Role - AVEO; AVEO; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer
James E. Signorovitch
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - I am an employee of Analysis Group, which received research funding from Novartis
Research Funding - I am an employee of Analysis Group, which received research funding from Novartis; Novartis
Peggy L. Lin
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Analysis Group; I am an employee of Analysis Group, which received research funding from Novartis; I am an employee of Analysis Group, which received research funding from Novartis; Novartis
Research Funding - I am an employee of Analysis Group, which received research funding from Novartis; Novartis
Zhimei Liu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Kenneth W. Culver
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Sumanta Kumar Pal
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Jeffrey A. Scott
No relevant relationships to disclose
Nicholas J. Vogelzang
Honoraria - Novartis
Research Funding - Novartis